About
Mission & Values
Leadership
Board of Directors
Collaborators
History
Contact Us
Platform
Human-First Discovery
®
Platform
IP Portfolio
Publications
Pipeline
Overview
Programs
Investors & News
Overview
Stock Information
Press Releases
Events & Presentations
Publications
Financials & Filings
Corporate Governance
Investor Resources
Contact IR
Careers
Overview
Open Positions
Press release
Evaluation of Engraftment and Diversity Following Open Label Administration of CP101, an Investigational Oral Microbiome Therapeutic for the Prevention of Recurrent C. Difficile Infection, in the PRISM-EXT Trial
Media contact:
Gabriella Linville-Engler
[email protected]
Investor contact:
Greg Perry
[email protected]
Contact us
[email protected]
617-229-6499
200 Inner Belt Road,
Suite 400, Somerville, MA, 02143
Policies
© 2023 Finch Therapeutics Group, Inc. All rights reserved.